Study to Evaluate the Safety and Efficacy of Tinlarebant in the Treatment of Stargardt Disease in Adolescent Subjects Lesion(s) in Adolescent Subjects With STGD1 (DRAGON)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05244304 |
Recruitment Status :
Active, not recruiting
First Posted : February 17, 2022
Last Update Posted : November 9, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Stargardt Disease 1 | Drug: Tinlarebant Drug: Placebo | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 104 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | This is a Phase 3 randomized, double-masked, parallel group, multicenter study to evaluate the efficacy and safety of Tinlarebant 5 mg in the treatment of adolescent subjects with STGD1. |
Masking: | Double (Participant, Investigator) |
Masking Description: | Eligible subjects will be randomly assigned to begin treatment in 2:1 ratio to receive the study drug (either Tinlarebant 5 mg or matching placebo) |
Primary Purpose: | Treatment |
Official Title: | Phase 3, Multicenter, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Tinlarebant in the Treatment of Stargardt Disease in Adolescent Subjects |
Actual Study Start Date : | March 28, 2022 |
Estimated Primary Completion Date : | August 2025 |
Estimated Study Completion Date : | October 2025 |
Arm | Intervention/treatment |
---|---|
Experimental: Tinlarebant
5 mg tablet taken orally once a day
|
Drug: Tinlarebant
Tinlarebant drug substance is a white to off-white substance and is dispensed as a tablet for oral administration. |
Placebo Comparator: Placebo
Placebo tablets for tinlarebant 5 mg are prepared similarly but use microcrystalline cellulose, NF, in place of the active drug substance and will be identical in size and appearance.
|
Drug: Placebo
Not active drug |
- To measure change in atrophic lesion size (definitely decreased autofluorescence, DDAF) by fundus autofluorescence (FAF) photography from baseline [ Time Frame: Baseline thru month 24 ]
- To measure the change in retinal thickness assessed by spectral-domain optical coherence tomography (SD-OCT) from baseline [ Time Frame: Baseline thru month 24 ]
- To measure the change in retinal morphology assessed by spectral-domain optical coherence tomography (SD-OCT) from baseline [ Time Frame: Baseline thru month 24 ]
- To measure change in BCVA (Best Corrected Visual Acuity) score measured by the EDTRS method from baseline [ Time Frame: Baseline thru month 24 ]
- To measure change in plasma concentration of RBP4 levels (μM) from baseline [ Time Frame: Baseline thru month 24 ]
- The correlation between change in plasma RBP4 level and the rate of lesion size growth (definitely decreased autofluorescence, DDAF) by fundus autofluorescence (FAF) photography from baseline [ Time Frame: Baseline thru month 24 ]
- To assess the systemic and ocular safety and tolerability of tinlarebant [ Time Frame: Baseline thru month 24 ]Frequency, duration, and severity of AEs
- To measure change in total decreased autofluorescence (DAF) by FAF photography from baseline [ Time Frame: Baseline thru month 24 ]
- To measure change in questionably decreased autofluorescence (QDAF) by FAF photography from baseline [ Time Frame: Baseline thru month 24 ]
- To measure change in quantitative autofluorescence (qAF) level from baseline [ Time Frame: Baseline thru month 24 ]
- To measure change in retinal sensitivity by microperimetry from baseline [ Time Frame: Baseline thru month 24 ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 12 Years to 20 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male or female subjects 12 to 20 years old, inclusive.
- Subject must have clinically diagnosed STGD1 (Stargardt disease 1) with at least 1 mutation identified in the ABCA4 gene.
- Subject must have a defined aggregate atrophic lesion size within 3 disc areas (7.62 mm2), as imaged by FAF in the study eye Subjects must have a BCVA of 20/200 or better for the study eye based on ETDRS letter score
- Subject and their parent(s) or legal guardian are willing to provide their consent on an Institutional Review Board (IRB)/Independent Ethics Committee (IEC)/Human Research Ethics Committee (HREC)-approved informed consent form (ICF) prior to participating in any study-related procedures.
- Subject agrees to comply with all protocol requirements.
Exclusion Criteria:
- Any ocular disease other than Stargardt (STGD1) at baseline that, in the opinion of the investigator, would complicate assessment of a treatment effect.
- History of ocular surgery in the study eye in the last 3 months.
- Investigational drug use of any kind in the last 3 months or within 5 half-lives of the investigational drug, whichever is shorter.
- Any prior gene therapy.
- Vitamin A (retinol) deficiency as defined as a retinol serum level less than 20 mcg/dL (=0.7 μmol/L).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05244304
United States, California | |
Belite Study Site | |
Palo Alto, California, United States, 94303 | |
United States, Florida | |
Belite Study Site | |
Gainesville, Florida, United States, 32607 | |
United States, Minnesota | |
Belite Study Site | |
Minneapolis, Minnesota, United States, 55435 | |
United States, New York | |
Belite Study Site | |
New York, New York, United States, 10032 | |
United States, Utah | |
Belite Study Site | |
Salt Lake City, Utah, United States, 84132 | |
Australia, New South Wales | |
Belite Study Site | |
Westmead, New South Wales, Australia | |
Australia, Victoria | |
Belite Study Site | |
East Melbourne, Victoria, Australia | |
Australia | |
Belite Study Site | |
South Brisbane, Australia | |
Belgium | |
Belite Study Site | |
Gent, Belgium | |
Belite Study Site | |
Leuven, Belgium | |
China | |
Belite Study Site | |
Beijing, China | |
Belite Study Site | |
Shanghai, China | |
France | |
Belite Study Site | |
Paris, France | |
Germany | |
Belite Study Site | |
Bonn, Germany | |
Belite Study Site | |
Gießen, Germany | |
Belite Study Site | |
Tübingen, Germany | |
Hong Kong | |
Belite Study Site | |
Kowloon, Hong Kong | |
Netherlands | |
Belite Study Site | |
Amsterdam, Netherlands | |
Belite Study Site | |
Nijmegen, Netherlands | |
Switzerland | |
Belite Study Site | |
Basel, Switzerland | |
Taiwan | |
Belite Study Site | |
Taipei, Taiwan | |
Belite Study Site | |
Taoyuan City, Taiwan | |
United Kingdom | |
Belite Study Site | |
London, United Kingdom | |
Belite Study Site | |
Southampton, United Kingdom |
Responsible Party: | Belite Bio, Inc |
ClinicalTrials.gov Identifier: | NCT05244304 |
Other Study ID Numbers: |
LBS-008-CT03 |
First Posted: | February 17, 2022 Key Record Dates |
Last Update Posted: | November 9, 2023 |
Last Verified: | November 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Stargardt Disease Macular Degeneration Eye Diseases, Hereditary Eye Diseases |
Retinal Degeneration Retinal Diseases Genetic Diseases, Inborn |